UK’s GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion

Markets Investing.com By Reuters 09 Jun 2026 06:12 1 min read

UK’s GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion

UK’s GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion

UK’s GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion

Read the full story on Investing.com → Opens the original article on www.investing.com

Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.